- Home
- MARPS vs QNTM Comparison
MARPS vs QNTM Comparison
Compare MARPS & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MARPS
- QNTM
- Stock Information
- Founded
- MARPS 1956
- QNTM 1998
- Country
- MARPS United States
- QNTM Canada
- Employees
- MARPS N/A
- QNTM N/A
- Industry
- MARPS Oil & Gas Production
- QNTM
- Sector
- MARPS Energy
- QNTM
- Exchange
- MARPS Nasdaq
- QNTM NYSE
- Market Cap
- MARPS 7.8M
- QNTM 8.7M
- IPO Year
- MARPS N/A
- QNTM N/A
- Fundamental
- Price
- MARPS $3.92
- QNTM $8.04
- Analyst Decision
- MARPS
- QNTM
- Analyst Count
- MARPS 0
- QNTM 0
- Target Price
- MARPS N/A
- QNTM N/A
- AVG Volume (30 Days)
- MARPS 2.6K
- QNTM 1.5M
- Earning Date
- MARPS 01-01-0001
- QNTM 05-13-2025
- Dividend Yield
- MARPS 8.44%
- QNTM N/A
- EPS Growth
- MARPS N/A
- QNTM N/A
- EPS
- MARPS 0.30
- QNTM N/A
- Revenue
- MARPS $945,496.00
- QNTM N/A
- Revenue This Year
- MARPS N/A
- QNTM N/A
- Revenue Next Year
- MARPS N/A
- QNTM N/A
- P/E Ratio
- MARPS $13.05
- QNTM N/A
- Revenue Growth
- MARPS N/A
- QNTM N/A
- 52 Week Low
- MARPS $3.76
- QNTM $2.70
- 52 Week High
- MARPS $6.50
- QNTM $44.72
- Technical
- Relative Strength Index (RSI)
- MARPS 51.16
- QNTM 60.11
- Support Level
- MARPS $3.85
- QNTM $6.45
- Resistance Level
- MARPS $3.95
- QNTM $12.45
- Average True Range (ATR)
- MARPS 0.03
- QNTM 1.66
- MACD
- MARPS 0.01
- QNTM 0.28
- Stochastic Oscillator
- MARPS 52.94
- QNTM 43.80
About MARPS Marine Petroleum Trust Units of Beneficial Interest
Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.